rc48-adc
Microsatellite Instability High
Sun Yat-sen Universityantibody_drug_conjugatePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Microsatellite Instability High cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pyrotinib Sun Yat-sen University | Phase 3 | B |
Tislelizumab Sun Yat-sen University | Phase 3 | B |
Dfn-15 Sun Yat-sen University | Phase 2 | CCC |
Toripalimab Sun Yat-sen University | Phase 2 | CCC |
Cyclophosphamide NextCure, Inc. | Phase 1/2 | CCC |
View all 12 →
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →